In the BioHarmony Drug Report Database
Romosozumab
Evenity (romosozumab) is an antibody pharmaceutical. Romosozumab was first approved as Evenity on 2019-04-09. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat osteoporosis. The pharmaceutical is active against sclerostin.
Trade Name
|
Evenity |
|---|---|
Common Name
|
romosozumab |
ChEMBL ID
|
CHEMBL2107874 |
Indication
|
osteoporosis, postmenopausal osteoporosis |
Drug Class
|
Monoclonal antibodies: humanized, bone target |
Image (chem structure or protein)
